Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ZVRA with free AI briefings, catalyst countdowns, and dilution alerts.

ZVRA · ZEVRA THERAPEUTICS, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$270.9M Cash on Hand
CF+ Cash Runway
Follow ZVRA by email Get an email when ZVRA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ZVRA, unsubscribe in one click. Privacy

📣 What ZVRA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Arimoclomol
FDA approved Sep 2024 · Miplyffa
Niemann-Pick Disease, Type C Phase 2/3 · NCT02612129 Completed
Serdexmethylphenidate And Dexmethylphenidate
FDA approved Mar 2021 · Azstarys
ADHD Phase 3 · NCT03460652 Completed
Sodium Phenylbutyrate
FDA approved Dec 2022 · Olpruva
Medium-chain Acyl-CoA Dehydrogenase Deficiency Phase 2 · NCT06773026 Recruiting
Celiprolol Vascular Ehlers-Danlos Syndrome Phase 3 · NCT05432466 Recruiting
Osanetant (ACER-801) Post-menopausal Vasomotor Symptoms Phase 1/2 · NCT05325775 Completed
Serdexmethylphenidate Idiopathic Hypersomnia Phase 2 · NCT05668754 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ZVRA holds $270.9M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ZVRA files for a raise →

👥 Who Owns ZVRA

Insiders 1.4% Institutions (232 holders) 79.9% Public and other holders 18.7%
HolderTypeShares% of sharesAs of
FMR LLC Institution (13G, 5%+) 5,562,781 9.35% 2026-09-30
Woodline Partners LP Institution (13G, 5%+) 4,785,771 8.04% 2026-06-30
Vanguard Capital Management Institution (13G, 5%+) 3,024,980 5.08% 2026-06-30
Neil F. McFarlane
President and CEO, Director · +375,000 options
Insider 417,225 0.70% 2026-10-10
R. LaDuane Clifton
Former CFO & Treasurer
Insider 143,515 0.24% 2025-12-31
John B Bode
Director · +49,600 options
Insider 123,400 0.21% 2026-03-24
Joshua Schafer
CCO · +110,333 options
Insider 62,278 0.10% 2026-02-03
Rahsaan Thompson
Chief Legal & Compliance · +141,667 options
Insider 37,569 0.06% 2026-08-14
Timothy J. Sangiovanni
SVP, Finance & Corp Controller · +60,000 options
Insider 29,590 0.05% 2026-02-03
Alvin Shih
Director · +60,000 options
Insider 20,000 0.03% 2025-09-12
Adrian W Quartel
Chief Medical Officer · +97,667 options
Insider 9,723 0.02% 2026-01-29
Tamara A Favorito
Director · +60,000 options
Insider 3,894 0.01% 2025-09-12

Share count 59,504,621 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ZVRA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ZVRA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.